# Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA

> **NCT00510692** · PHASE2,PHASE3 · COMPLETED · sponsor: **S.L.A. Pharma AG** · enrollment: 58 (actual)

## Conditions studied

- Familial Adenomatous Polyposis Coli
- FAP

## Interventions

- **DRUG:** Eicosapentanoic Acid (EPA)
- **PROCEDURE:** Endoscopy
- **PROCEDURE:** Biopsies taken
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00510692
- **Lead sponsor:** S.L.A. Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2014-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510692, "Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00510692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*